Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen Research & Development, LLC
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A diagnosis of RA meeting the American College of Rheumatology 1987 (ACR1987) criteria, obtained at least three months prior to dosing with the trial product
Subjects with active RA having a Disease Activity Score (DAS28-CRP) of 4.5 or more, at least five tender and five swollen joints (can be the same), including one swollen wrist or at least two swollen ipsilateral metacarpophalangeal (MCP) joints (second to fifth)
Concomitant treatment with methotrexate (MTX) (7.5-25 mg/week) for at least 12 weeks, with stable dose for at least 4 weeks prior to dosing
Ability to be examined by Magnetic Resonance Imaging (MRI)
Having failed no biologic therapies for RA and no more than two non-biologic disease modifying antirheumatic drugs
You may not be if
Chronic inflammatory autoimmune disease other than RA (rheumatoid arthritis)
Any ongoing chronic or active infectious disease or microbial infection requiring systemic oral or intravenous treatment against infection within 1 month prior to trial start
Body mass index (BMI) below or equal to 18 or above or equal to 40 kg/m\^2
Clareo Health | Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)
